Heart-healthy NSAIDs?
This article was originally published in The Tan Sheet
Executive Summary
University of Pennsylvania researchers believe the findings of their new study suggest "the possibility of a new class of nonsteroidal anti-inflammatory drugs (NSAIDs) that steer clear of heart-disease risk and work to reduce it," according to a UPenn release. Deleting the inflammation enzyme microsomal (m)-PGE synthase (PGES)-1 gene in mice predisposed to hardening of the arteries had a "dramatic effect" on the development of atherosclerosis in male and female mice, Miao Wang, PhD, School of Medicine, UPenn, et al., found. Moreover, the deletion of mPGES-1 did not raise blood pressure or predispose the mice to thrombosis like COX-2 inhibition or deletion, the authors report in the Sept. 14 online edition of the Proceedings of the National Academy of Sciences. The PNAS study builds on a study published by the researchers earlier this year in the Journal of Clinical Investigation (1"The Tan Sheet" April 17, 2006, p. 8). The Journal of the American Medical Association released a study this week highlighting the cardiovascular risks associated with taking COX-2s...
You may also be interested in...
COX-2 Heart Risk Mechanism Suggested By Mouse Study Results
Researchers may have identified the mechanism by which COX-2 inhibitors contribute to the risk of cardiovascular events, a study published in the April Journal of Clinical Investigation finds
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.